- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02663583
Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell
Observational Parallel Cohort Study of Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Baseline Visit:
If participant agrees to take part in this study, they will complete the following tests and procedures at their baseline visit. This baseline visit will take place before participant's treatment with IMPT or TORS:
- Participant will complete questionnaires about any symptoms of cancer they may be having and how they affect their daily life at work and at home, their diet, and their speech.
- Participant will complete the Dysphagia Inventory. This is a questionnaire about how difficult it is to swallow.
- The study staff will measure how wide participant can open their jaw to see if their treatment may cause any jaw opening limitations.
It should take about 30 minutes to complete all of the questionnaires.
As part of participant's baseline visit, information below will be collected from their medical record:
- Participant's medical history
- The results of participant's physical exam including their weight and any recent weight loss.
- Any other diseases participant may have and any drugs they are currently taking.
- Participant's current smoking status and smoking history.
Activity Bands:
The study staff will either give participant an activity band at their baseline visit or they will be mailed an activity wristband. Participant will be asked to wear the band 24 hours a day for 1 week leading up to all study visits. The wristband will record how active participant is and how much they sleep. The study staff will show participant how to wear and use the wristband.
Study Visits:
Participant will complete the following study procedures after they complete treatment with either IMPT or TORS, and at 3 and 6 months after that.
- The data from participant's wristband will be collected.
- Participant will complete the same questionnaires they did at baseline.
- At participant's 3 month visit only, the study staff will measure how wide they can open their jaw to see if their treatment may cause any jaw opening limitations.
IMPT patients only:
If participant is receiving IMPT, they will complete the questionnaires they completed at the baseline visit once a week while they are receiving treatment.
Length of Study:
Participant's active participation in this study will be over after the 6 month study visit.
Participant will return the wristband to the study staff after their participation is over. If participant loses or damages the wristband while they are on study, another one will be provided to them at no cost.
This is an investigational study.
Up to 44 participants will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Neil Gross, MD
- Phone Number: 713-792-6920
- Email: ngross@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
Contact:
- MD Anderson Health Information Specialist
- Phone Number: 877-632-6789
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Histologically documented or suspected, previously untreated OPSCC (Clinical Stage I-Va; Tx,0-2, N0-2b) eligible for standard of care single-modality treatment with either IMPT or TORS. Patients with suspected OPSCC must have a diagnosis confirmed prior to treatment per the current clinical standard of care
- Eastern Cooperative Oncology Group (ECOG) = 0, 1, or 2
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Intensity-Modulated Proton Therapy or( IMPT) Group
Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months. Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months. Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits. |
Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months. TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
Other Names:
Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months. TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
Other Names:
Activity bands given to participant at baseline.
Participant wears the band 24 hours a day for 1 week leading up to all study visits.
|
TransOral Robotic Surgery (TORS) Group
Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months. Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months. Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits. |
Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months. TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
Other Names:
Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months. TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
Other Names:
Activity bands given to participant at baseline.
Participant wears the band 24 hours a day for 1 week leading up to all study visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Functional Outcome After Treatment with Either Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) in Participants with Low-Risk Oropharynx Squamous Cell Carcinoma (OPSCC)
Time Frame: 6 months
|
Functional outcome measured by using longitudinal digital wristband activity monitoring of study participants.
|
6 months
|
Objective Functional Outcome After Treatment with Either Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) in Participants with Low-Risk Oropharynx Squamous Cell Carcinoma (OPSCC)
Time Frame: 6 Months
|
Functional outcome measured by using patient-reported outcome (PRO) measures from the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDADI-HN).
|
6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Neil Gross, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA15-0744
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharynx Squamous Cell Carcinoma
-
University of Michigan Rogel Cancer CenterBristol-Myers SquibbActive, not recruitingOropharynx Squamous Cell CarcinomaUnited States
-
Region SkaneRecruitingOropharynx Squamous Cell CarcinomaSweden
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSquamous Cell Carcinoma of OropharynxUnited States
-
University of ChicagoNational Cancer Institute (NCI)TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the OropharynxUnited States
-
University of VirginiaNot yet recruitingSquamous Cell Carcinoma of the OropharynxUnited States
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United Kingdom; Oracle Cancer TrustRecruitingSquamous Cell Carcinoma of the OropharynxUnited Kingdom
-
CMR Surgical LtdLiverpool University Hospitals NHS Foundation Trust; Sintesi Research S.r.l.RecruitingSquamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma, Unknown PrimaryUnited Kingdom
-
Joseph CalifanoJohns Hopkins University; NYU Langone Health; Greater Baltimore Medical Center; San Diego Veterans Healthcare System and other collaboratorsCompletedSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Squamous Cell Carcinoma of the OropharynxUnited States
-
National Cancer Institute (NCI)CompletedStage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditionsUnited States
-
ISA PharmaceuticalsRegeneron PharmaceuticalsActive, not recruitingSquamous Cell Carcinoma of the Oropharynx | HPV16 PositiveNetherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Clinical Trials on Symptom Questionnaires
-
M.D. Anderson Cancer CenterNational Institute of Dental and Craniofacial Research (NIDCR)Unknown
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.CompletedSARS-CoV-2 | Coronavirus Disease 2019 (COVID-19)United States
-
M.D. Anderson Cancer CenterActive, not recruitingHead and Neck Cancer | Malignant Neoplasms of Lip Oral Cavity and PharynxUnited States
-
M.D. Anderson Cancer CenterRecruiting
-
Dana-Farber Cancer InstituteNational Institute of Nursing Research (NINR)CompletedAcute Myeloid Leukemia (AML)United States
-
Weill Medical College of Cornell UniversityWithdrawnIschemia | Stress, MentalUnited States
-
Dana-Farber Cancer InstituteActive, not recruiting
-
The Functional Gut ClinicRosa BiotechRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Gastrointestinal Cancer | Disease (or Disorder); GynecologicalUnited States
-
M.D. Anderson Cancer CenterNovartis PharmaceuticalsUnknown